Literature DB >> 28906148

Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?

Jonah Rubin1, Julissa Alvarez1, Sergio Teruya1, Adam Castano1, Ronald A Lehman2, Mark Weidenbaum2, Jeffrey A Geller2, Stephen Helmke1, Mathew S Maurer1.   

Abstract

Transthyretin cardiac amyloidosis (ATTR-CA) causes a restrictive cardiomyopathy in older adults, often diagnosed at advanced stages when emerging therapies in late phase clinical trials may not have clinical benefit. This investigation aimed to detect clinical entities that may provide more advanced warning of ATTR-CA. Since ATTR preferentially deposits in ligaments, tendons, and articular cartilage, we hypothesized that ATTR-CA patients have a greater prevalence of total hip (THA) and knee (TKA) arthroplasties compared with the general population, and that arthroplasty occurs significantly before ATTR-CA diagnosis. Three-hundred and thirteen patients with cardiac amyloidosis (172 with ATTR-CA, 141 with light-chain) from our institutional database were analyzed and compared to published data in over 300 million patients. Overall, 23.3% of patients with ATTR-CA and 9.2% of patients with light-chain cardiac amyloidosis (AL-CA) underwent lower extremity arthroplasty. Compared to the general population, both THA and TKA were significantly more common among patients with ATTR-CA (THA: RR 5.61, 95% CI 2.25-4.64; TKA: RR 3.32, 95% CI 2.25-4.64) but not those with AL-CA (THA: RR 1.87, 95% CI 0.85-4.08; TKA: RR 1.42, 95% CI 0.73-2.84). On an average, arthroplasty occurred 7.2 years before ATTR-CA diagnosis.

Entities:  

Keywords:  Cardiac amyloidosis; arthroplasty; light-chain; transthyretin

Mesh:

Year:  2017        PMID: 28906148     DOI: 10.1080/13506129.2017.1375908

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  17 in total

1.  Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis.

Authors:  Andrew J Einstein; Igor Shuryak; Adam Castaño; Akiva Mintz; Mathew S Maurer; Sabahat Bokhari
Journal:  J Nucl Cardiol       Date:  2018-05-30       Impact factor: 5.952

Review 2.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

3.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2020-04       Impact factor: 5.952

Review 4.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Sabahat Bokhari; Thibaud Damy; Sharmila Dorbala; Brian M Drachman; Marianna Fontana; Martha Grogan; Arnt V Kristen; Isabelle Lousada; Jose Nativi-Nicolau; Candida Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Ronald Witteles; Giampaolo Merlini
Journal:  Circ Heart Fail       Date:  2019-09-04       Impact factor: 8.790

5.  Epigenomic Profiles of African-American Transthyretin Val122Ile Carriers Reveals Putatively Dysregulated Amyloid Mechanisms.

Authors:  Gita A Pathak; Frank R Wendt; Antonella De Lillo; Yaira Z Nunez; Aranyak Goswami; Flavio De Angelis; Maria Fuciarelli; Henry R Kranzler; Joel Gelernter; Renato Polimanti
Journal:  Circ Genom Precis Med       Date:  2021-01-11

6.  ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.

Authors:  Thomas H Brannagan; Michaela Auer-Grumbach; John L Berk; Chiara Briani; Vera Bril; Teresa Coelho; Thibaud Damy; Angela Dispenzieri; Brian M Drachman; Nowell Fine; Hanna K Gaggin; Morie Gertz; Julian D Gillmore; Esther Gonzalez; Mazen Hanna; David R Hurwitz; Sami L Khella; Mathew S Maurer; Jose Nativi-Nicolau; Kemi Olugemo; Luis F Quintana; Andrew M Rosen; Hartmut H Schmidt; Jacqueline Shehata; Marcia Waddington-Cruz; Carol Whelan; Frederick L Ruberg
Journal:  Orphanet J Rare Dis       Date:  2021-05-06       Impact factor: 4.123

Review 7.  Estimating the Gender Distribution of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Florint Kroi; Nils Fischer; Ana Gezin; Mahmoud Hashim; Mark Hermannes Rozenbaum
Journal:  Cardiol Ther       Date:  2020-12-14

8.  Amyloid arthropathy in smoldering myeloma: Do not take it lightly.

Authors:  Eli Muchtar; Rebecca L King; Ellen D McPhail; Matthew P Thorpe; Wilson Gonsalves; Floranne Ernste; Martha Grogan; Angela Dispenzieri; Morie A Gertz
Journal:  Leuk Res Rep       Date:  2021-04-24

Review 9.  Updates in Cardiac Amyloidosis Diagnosis and Treatment.

Authors:  Lily K Stern; Michelle M Kittleson
Journal:  Curr Oncol Rep       Date:  2021-03-16       Impact factor: 5.075

10.  Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis.

Authors:  P Eldhagen; S Berg; L H Lund; P Sörensson; O B Suhr; P Westermark
Journal:  J Intern Med       Date:  2021-01-07       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.